Highlights Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm Other stock markets 11:03:05 2024-05-17 am EDT			5-day change	1st Jan Change
1.628 ^SEK	-0.61%		+3.69%	-4.12%

Apr. 26	Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round	Jan. 17	MT
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise	Nov. 17	MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery	23-09-19	CI
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection	23-03-13	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data	23-02-14	CI
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Karolinska Development Partakes In Danish Dermatology Company Henlez' Seed Financing	22-10-24	MT
Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin	22-09-27	CI
Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria	22-09-02	CI
Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047	22-08-19	CI
Interim Report - January-June 2022	22-08-19	GL
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Karolinska Development-backed Promimic Launches US Joint Venture with Danco Medical	22-07-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Karolinska Development AB

Equities

KDEV

SE0002190926

Highlights

Filters